A role for cardiotrophin-1?

Hypertension

Volumn 63, Issue 3, 2014, Pages 468-474

  Moreno, María U ^a   San José, Gorka ^a   Pejenaute, Álvaro ^a,b   Landecho, Manuel F ^c   Díez, Javier ^a   Beloqui, Óscar ^c   Fortuño, Ana ^c   Zalba, Guillermo ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

cardiotrophin 1; hypertension; hypertrophy, left ventricular; NADPH oxidase; superoxides

Indexed keywords

CARDIOTROPHIN 1; CYTOKINE; MULTIENZYME COMPLEX; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ARTICLE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HUMAN; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIOTROPHIN 1; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; NADPH OXIDASE; SUPEROXIDES;

CYTOKINES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES;

EID: 84894486090     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01470     Document Type: Article

References (35)

1. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
2. Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, de Lemos JA, Drazner MH. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension. 2007;49:1385-1391.
3. Yan AT, Yan RT, Cushman M, Redheuil A, Tracy RP, Arnett DK, Rosen BD, McClelland RL, Bluemke DA, Lima JA. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: Insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2010;31:875-882.
4. Doddddrffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999;34:113-117.
5. Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. Coron Artery Dis. 2001;12:455-461.
6. Zhang M, Shah AM. Role of reactive oxygen species in myocardial remodeling. Curr Heart Fail Rep. 2007;4:26-30.
7. Zalba G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, Díez J. Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension. 2001;38:1395-1399.
8. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev. 2007;87:245-313.
9. Fortuño A, Oliván S, Beloqui O, San José G, Moreno MU, Díez J, Zalba G. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens. 2004;22:2169-2175.
10. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: Role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens. 2001;19:1245-1254.
11. Fortuño A, Bidegain J, San José G, Robador PA, Landecho MF, Beloqui O, Díez J, Zalba G. Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. J Hypertens. 2009;27:1420-1430.
12. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460.
13. Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG, Schneiderman N, McCabe PM. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab. 2008;295:E1495-E1501.
14. El-Benna J, Dang PM, Gougerot-Pocidalo MA. Priming of the neutrophil NADPH oxidase activation: Role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol. 2008;30:279-289.
15. Pennica D, Shaw KJ, Swanson TA, Moore MW, Shelton DL, Zioncheck KA, Rosenthal A, Taga T, Paoni NF, Wood WI. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/ gp130 signaling complex. J Biol Chem. 1995;270:10915-10922.
16. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A. 1995;92:1142-1146.
17. González A, López B, Martín-Raymondi D, Lozano E, Varo N, Barba J, Serrano M, Díez J. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens. 2005;23:2297-2304.
18. López B, González A, Querejeta R, Barba J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. J Hypertens. 2009;27:418-424.
19. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
20. Schillaci G, Pirro M, Pucci G, Ronti T, Vaudo G, Mannarino MR, Porcellati C, Mannarino E. Prognostic value of elevated white blood cell count in hypertension. Am J Hypertens. 2007;20:364-369.
21. Chon H, Verhaar MC, Koomans HA, Joles JA, Braam B. Role of circulating karyocytes in the initiation and progression of atherosclerosis. Hypertension. 2006;47:803-810.
22. Chon H, Gaillard CA, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, van Leenen D, Holstege FC, Joles JA, Bluyssen HA, Koomans HA, Braam B. Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension. 2004;43:947-951.
23. Devaux B, Scholz D, Hirche A, Kloddddvekorn WP, Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997;18:470-479.
24. Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, Tsutsui H, Takeshita A. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: Roles of oxidative stress and inflammation. Circulation. 2002;106:362-367.
25. Libby P, Lee RT. Matrix matters. Circulation. 2000;102:1874-1876.
26. Zalba G, Fortuño A, Orbe J, San José G, Moreno MU, Belzunce M, Rodríguez JA, Beloqui O, Páramo JA, Díez J. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: Implications for human atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:587-593.
27. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43:2116-2123.
28. Fritzenwanger M, Meusel K, Foerster M, Kuethe F, Krack A, Figulla HR. Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. Cytokine. 2007;38:137-144.
29. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-Type cytokine signalling and its regulation. Biochem J. 2003;374(pt 1):1-20.
30. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much?. Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102:215-222.
31. Roselló-Lletí E, Rivera M, Martínez-Dolz L, González Juanatey JR, Cortés R, Jordán A, Morillas P, Lauwers C, Calabuig JR, Antorrena I, de Rivas B, Portolés M, Bertomeu V. Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens. 2009;22:444-450.
32. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225-231.
33. Fortuño A, Bidegain J, Robador PA, Hermida J, López-Sagaseta J, Beloqui O, Díez J, Zalba G. Losartan metabolite EXP3179 blocks NADPH oxidasemediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension. Hypertension. 2009;54:744-750.
34. Díez J. Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. Clin Ther. 2006;28:832-848.
35. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther. 2008;120:254-291.